Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imatinib Teva

Teva Pharma logo

US states sue generic firms over ‘inflated’ prices

Companies accused of “multi-billion dollar fraud" and conspiracy

- PMLiVE

Novartis builds case for SMA gene therapy as FDA verdict looms

One shot therapy provided rapid improvement in motor function

- PMLiVE

CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

Opioid dependence therapy and Pfizer's PARP inhibitor also recommended

- PMLiVE

Alcon spun off, leaner Novartis raises profit forecast

Expects three new launches in 2019

- PMLiVE

Poseida gets Novartis backing for myleoma CAR-T challenger

San Diego firm joins crowded field

- PMLiVE

Novartis makes case for gene therapy Zolgensma in SMA

New data revealed ahead of FDA review

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Teva’s migraine injection approved in Europe

Third anti-CGRP treatment to hit the market

Novartis day

Novartis claims first place for psoriasis drug Cosentyx in China

Trial data from China helped support filing

- PMLiVE

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Acquires its portfolio of NLRP3 targeting drugs

- PMLiVE

FDA approves Novartis’ next-gen MS drug Mayzent

Drug reduces risk of disease progression

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links